Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01455870 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
A Phase 3 study of Type 2 Diabetes, sponsored by Intarcia Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 535
- Enrollment target
- 20
- Study locations
NCT01455870 is a Phase 3 study of Type 2 Diabetes that has completed, run by Intarcia Therapeutics. The registered enrollment target is 535 participants, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (51% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT01455870, a Phase 3 study of Type 2 Diabetes, has completed, sponsored by Intarcia Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 535 participants
- Enrollment target
- 20
- Study locations
Study Summary
Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.
Conditions Studied
Interventions
- DRUG sitagliptin
- DRUG ITCA 650 60 mcg/day
Study Locations (20)
California
- - Long Beach
- - Los Angeles
- - San Diego
- - San Mateo
- - Tustin
- - Valley Village
- - Walnut Creek
Florida
- - Boca Raton
- - Clearwater
- - Coral Gables
- - Miami
- - North Miami Beach
- - Pembroke Pines
Illinois
- - Chicago
- - Chicago
Indiana
- - Avon
- - Franklin
Alabama
- - Birmingham
Arizona
- - Chandler
Georgia
- - Canton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 535 participants |
| Start Date | 2013-05 |
| Est. Completion | 2015-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01455870
The ClinicalTrials.gov registry entry for NCT01455870 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 535 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,101-participant average among 288 other Type 2 Diabetes trials with a reported enrollment target (51% lower). The listed sponsor is Intarcia Therapeutics, which has 16 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which sitagliptin is the first listed.
NCT01455870 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Illinois.
Frequently Asked Questions
What is clinical trial NCT01455870 about?
NCT01455870 is a clinical study titled "A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes". Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.
What is the current status of trial NCT01455870?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 535 participants. The study started on 2013-05. Estimated completion is 2015-07.
What conditions does trial NCT01455870 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT01455870?
The interventions under investigation include: sitagliptin (DRUG), ITCA 650 60 mcg/day (DRUG).
Who is sponsoring clinical trial NCT01455870?
This trial is sponsored by Intarcia Therapeutics, which has 16 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01455870 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
-
A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)
RECRUITING · Phase 3
-
Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity
ACTIVE NOT RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes and Moderate or Severe Renal Impairment, With Inadequate Glycemic Control on Basal Insulin, With or Without Metformin and/or SGLT2 Inhibitor (TRANSCEND-T2D-3)
ACTIVE NOT RECRUITING · Phase 3
-
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.